Strategies for administration of tissue plasminogen activator

Area of Science:

• Cardiology
• Pharmacology
• Emergency Medicine

Background:

• Recombinant tissue plasminogen activator (t-PA) has been a cornerstone of thrombolytic therapy since 1984.
• Understanding optimal administration methods for t-PA has evolved significantly.
• Experimental data informs clinical trials on thrombolysis.

Purpose of the Study:

• Review experimental data on t-PA administration, adjunctive treatments, and novel plasminogen activators.
• Summarize major clinical findings in acute myocardial infarction (AMI) treatment with t-PA.
• Highlight advancements setting the stage for large-scale mortality reduction trials.

Main Methods:

• Review of experimental data regarding bolus t-PA and new plasminogen activators.
• Analysis of clinical trial findings for acute myocardial infarction.
• Evaluation of adjunctive treatments like intravenous heparin.

Main Results:

• Significant reduction in mortality and improved cardiac function with t-PA.
• Increased risk of serious bleeding complications observed with high t-PA doses (150 mg).
• Accelerated "front-loaded" regimens demonstrate rapid infarct vessel recanalization.
• Conjunctive intravenous heparin is crucial for optimal outcomes.
• Emerging potential for new, combined plasminogen activator therapies.

Conclusions:

• Optimized t-PA administration and adjunctive therapies improve outcomes in acute myocardial infarction.
• Careful dose selection and combination therapies are key to balancing efficacy and safety.
• Ongoing research and large trials like GUSTO continue to refine thrombolytic strategies.